Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCR040
- Development stage
- Phase 2
- Lead developer
- Histocell
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HCR040 is an allogeneic cell therapy developed by Histocell, consisting of adipose-derived adult mesenchymal stem cells (MSCs) designated as HC016. These cells are expanded and pulsed with hydrogen peroxide (H2O2) during the manufacturing process to enhance their resistance to oxidative stress and boost their immunomodulatory properties. This priming is intended to improve cell survival and therapeutic efficacy when administered into the highly inflammatory and oxidative environment characteristic of Acute Respiratory Distress Syndrome (ARDS). HCR040 aims to reduce pulmonary inflammation and promote tissue repair in patients suffering from severe respiratory failure.
- Other names
- HC016HC-016HC 016adipose derived mesenchymal stromal cellsallogeneic adipose-derived adult mesenchymal stem cells
Beyond the preview
Go deeper on HCR040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCR040.